1. 日本眼炎症学会ぶどう膜炎診療ガイドライン作成委員会, ぶどう膜炎診療ガイド ライン. Jpn J Ophthalmol. 2019;123:635–695.
2. Ohguro N, Sonoda K-H, Takeuchi M, et al. The 2009 prospective multi-center pidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432–4.
3. Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the Worldwide Epidemiology of Uveitis. Eur. J. Ophthalmol. 2013;23:705–717.
4. Acharya NR, Tham VM, Esterberg E, Borkar DS, Parker JV, Vinoya AC, Uchida A. Incidence and Prevalence of Uveitis: Results From the Pacific Ocular Inflammation Study. JAMA Ophthalmol. 2013;131:1405–1412.
5. Joltikov KA, Lobo-Chan A-M. Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic ReviewEpidemiology of uveitis. Front. Med. 2021; 8:695904..
6. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J. Rheumatol. 2004;31:1362–1368.
7. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet. 2016;388:1183–1192.
8. Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, Kaburaki T, Kramer M, Lim LL, Muccioli C, Nguyen QD, Van Calster J, Cimino L, Kron M, Song AP, Liu J, Pathai S, Camez A, Schlaen A, van Velthoven MEJ, Vitale AT, Zierhut M, Tari S, Dick AD. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing OpenLabel Study: VISUAL III. Ophthalmology. 2018;125:1075–1087.
9. Li B, Li H, Zhang L, Zheng Y. Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Pharmacol. 2021;12:899.
10. Hu Y, Huang Z, Yang S, Chen X, Su W, Liang D. Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2020;11:941.
11. Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current Evidence of Anti– Tumor Necrosis Factor α Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis Approach of Individual Drugs. Arthritis Care Res. 2014;66:1073–1084.
12. Li Y, Mao X, Tang X, Mao H. Efficacy and Safety of Anti-TNFα Therapy for Uveitis Associated with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. Rheumatol. Ther. 2021;8:711–727.
13. Horiguchi N, Kamoi K, Horie S, Iwasaki Y, Kurozumi-Karube H, Takase H, Ohno-Matsui K. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome. Sci. Rep. 2020;10:22227.
14. Guignard S, Gossec L, Salliot C et al.: Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006; 65: 1631-4.
15. Wenling D, Joshi A, Reilly P, Jalund Hwala YJ, Mittal M, Bao Y: Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin 2014; 30: 2515- 21.
16. Ming S, Xie K, He H, et al. Efficacy and safety of adalimumab in the treatment of noninfectious uveitis: a meta-analysis and systematic review. DDDT. 2018;12:2005–2016.
17. Li B, Li H, Zhang L, et al. Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021;12:673984.
18. Hu Y, Huang Z, Yang S, et al. Effectiveness and Safety of Anti-Tumor Necrosis FactorAlpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2020;11:941.
19. Silpa-archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmologica. 2016;94:e400–e406.
20. de Boer JH, van Haren MAC, de Vries-Knoppert WAEJ, et al. Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Current Eye Research. 1992;11:181–186.
21. Franks WA, Limb GA, Stanford MR, et al. Cytokines in human intraocular inflammation. Current Eye Research. 1992;11:187–191.
22. Perez V, Papaliodis G, Chu D, et al. Elevated Levels of Interleukin 6 in the Vitreous Fluid of Patients with Pars Planitis and Posterior Uveitis: The Massachusetts Eye & Ear Experience and Review of Previous Studies. Ocular Immunology and Inflammation. 2004;12:205–214.
23. Mesquida M, Molins B, Llorenç V, et al. Long-Term Effects of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema. Ophthalmology. 2014;121:2380–2386.
24. Yepes-Nuñez JJ, Urrútia G, Romero-García M, Alonso-Fernández S. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev. Espanola Cardiol. Engl. Ed. 2021;74:790–799.
25. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
26. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M, Aromataris E. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid. Synth. 2020;18:2127–2133.
27. “GRADEpro”: , cited 10 September. 2021.
28. Cordero-Coma M, Calvo-Río V, Adán A, Blanco R, Álvarez-Castro C, Mesquida M, Calleja S, González-Gay MA, Ruíz de Morales JG. Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience. Mediators Inflamm. 2014;2014:e717598.
29. Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, Franceschini R, Bacherini D, Frediani B, Galeazzi M, Tosi GM, Cantarini L. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet’s Disease. Ocul. Immunol. Inflamm. 2019;27:58–63.
30. Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritisassociated uveitis unresponsive to Adalimumab. Pediatr. Rheumatol. 2021;19:132.
31. Bentum RE van, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, Kok MR, Schilder AM, Verhoef M, Horst-Bruinsma IE van der. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GOEASY Study. J. Rheumatol. 2019;46:153–159.
32. Yazgan S, Celik U, Işık M, Yeşil NK, Baki AE, Şahin H, Gencer E, Doğan İ. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int. Ophthalmol. 2017;37:139–145.
33. Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term Treatment with Golimumab for Severe Uveitis. Ocul. Immunol. Inflamm. 2014;22:90–95.
34. Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M, GallegoFlores A, Veroz R, Torre I, Hernández FF, Atanes A, Loricera J, González-Vela MC, Palmou N, Hernández JL, González-Gay MA. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin. Arthritis Rheum. 2016;46:95– 101.
35. Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, Fernández-Díaz C, Mesquida M, Adán A, Hernández MV, Cordero-Coma M, Maiz Alonso O, Díaz-Valle D, Fernández-Cid C, Ruiz-Moreno O, Hernández JL, González-Gay MA, Blanco R. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin. Exp. Rheumatol. 2018;36:652–657.
36. Elliott DB. The good (logMAR), the bad (Snellen) and the ugly (BCVA, number of letters read) of visual acuity measurement. Ophthalmic Physiol. Opt. 2016;36:355–358.
37. Williams MA, Moutray TN, Jackson AJ. Uniformity of Visual Acuity Measures in Published Studies. Invest. Ophthalmol. Vis. Sci. 2008;49:4321–4327.
38. Tsou BC, Bressler NM. Visual Acuity Reporting in Clinical Research Publications. JAMA Ophthalmol. 2017;135:651–653.
39. Tosi GM, Sota J, Vitale A, Rigante D, Emmi G, Lopalco G, Guerriero S, Orlando I, Iannone F, Frediani B, Angotti R, Messina M, Galeazzi M, Vannozzi L, Cantarini L, Fabiani C. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin. Exp. Rheumatol. 2019;37:680–683.
40. Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A, Koletzko S, Kugathasan S, Markowitz J, Ruemmele FM, Veereman G, Winter H, Masel N, Shin CR, Tang KL, Thayu M. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology, 2017;152:1901- 1914.e3.
41. Carmona L, Abasolo L, Descalzo MA, Pérez-Zafrilla B, Sellas A, de Abajo F, GomezReino JJ. Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists. Semin. Arthritis Rheum. 2011;41:71–80.
42. Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Van Calster J, Cimino L, Adan A, Goto H, Kaburaki T, Kramer M, Vitale AT, Kron M, Song AP, Liu J, Pathai S, Douglas KM, Schlaen A, Muccioli C, Van Velthoven MEJ, Zierhut M, Rosenbaum JT. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. 2021;128:899–909.
43. Xiong A, Liu D, Chen H, et al. The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies. Front Pharmacol. 2021;12:620340.
44. “シンポニー皮下注 50mg シリンジ/シンポニー皮下注 50mg オートインジェクタ ー (添付文書)”: , cited 22 July. 2022.
45. Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, Kurz PA, Lim L, Mackensen F, Pickard TD, Rosenbaum JT. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch. Ophthalmol. Chic. Ill 1960. 2009;127:819–822.
46. Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, Pasadhika S, Lee ST, Sardos A de S, Butler NJ, Tessler HH, Smith JR, Rosenbaum JT. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br. J. Ophthalmol. 2013;97:481–486.
47. Noriko O, Noriko O, Ayaka T, Ayaka T, Junko H, Junko H. Two Cases of Scleritis Induced as a Paradoxical Reaction to CTLA4Ig. J. Eye. 2020;37:636–639.
48. AlBloushi AF, Alfawaz AM, Asrar AMAE. Implications of COVID-19 infection on patients with uveitis under biologic treatment. Br. J. Ophthalmol. 2021.
49. Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32:S75-79.
50. Deuter CME, Zierhut M, Igney-Oertel A, et al. Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment. Ocular Immunology and Inflammation. 2017;25:215–220.
51. Tappeiner C, Mesquida M, Adán A, et al. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. The Journal of Rheumatology. 2016;43:2183–2188.
52. Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti–Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis & Rheumatology. 2017;69:668–675.
53. Mesquida M, Molins B, Llorenç V, et al. Twenty-four Month Follow-up of Tocilizumab Therapy for Refractory Uveitis-related Macular Edema. Retina. 2018;38:1361–1370.
54. Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. American Journal of Ophthalmology. 2017;183:71–80.
55. Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. Ocular Immunology and Inflammation. 2018;26:1005–1014.
56. Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology. 2018;57:856–864.
57. Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. American Journal of Ophthalmology. 2019;200:85–94.
58. Wennink RAW, Ayuso VK, de Vries LA, et al. Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis. Ocular Immunology and Inflammation. 2021;29:21–25.
59. Maleki A, Manhapra A, Asgari S, et al. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis. Ocular Immunology and Inflammation. 2021;29:14–20.
60. “アクテムラ点滴静注用 80mg/アクテムラ点滴静注用 200mg/アクテムラ点滴静 注用 400mg (添付文書)”: , cited 22 July. 2022.